By a News Reporter-Staff News Editor at Clinical Trials Week -- Acucela Inc. (TOKYO:4589), a clinical-stage biotechnology company that specializes in discovering and developing novel therapeutics to treat and slow the progression of ... 4 Traders, 1 month ago
Acucela completes patient enrollment in Phase 2b/3 clinical trial of emixustat hydrochloride - News-Medical.Net, 1 month ago
Acucela Completes Enrollment in the Emixustat Hydrochloride Phase 2b/3 Clinical Trial - 4 Traders, 1 month ago
1 images for "Emixustat Hydrochloride"
Acucela, a US-based clinical-stage biotechnology firm, has completed the patient enrollment in its ongoing Phase IIb/III clinical trial evaluating emixustat in subjects with geographic atrophy (GA) associated with dry age-related macular ...Pharmaceutical Business Review, 1 month ago
on your WebpageAdd Widget >Get your members hooked!